ERBB2 and breast carcinoma: T-DM1 has been extensively studied in preclinical models of breast cancer [15,18] These studies demonstrated that T-DM1 has dual mechanisms of action: selective delivery of DM1 to the HER-2-positive tumor cells and activation of antibody-dependent cellular cytotoxicity.